12:00 AM
 | 
Dec 03, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Dalantercept: Phase II started

Acceleron began an open-label, U.S. Phase II trial to evaluate subcutaneous dalantercept given every 21 days in about 52 patients. NIH's National Cancer Institute (NCI) is providing funding...

Read the full 119 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >